Herantis Pharma PLC · OMXHEX:HRTIS

Herantis Pharma — TreatER webinar 2020

14 slides from Herantis Pharma's conference presentation, Nov 18, 2020

  1. Slide 1: CDNF – Potential in prevention of dopamine neuron degeneration and stimulation of neuron regeneration

    CDNF – Potential in prevention of dopamine neuron degeneration and stimulation of neuron regeneration Henri J. Huttunen, CSO Herantis Pharma Plc TreatER webinar 18 Nov 2020 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.

  2. Slide 2: Potential To Revolutionize Parkinson's Disease Treatment

    Potential To Revolutionize Parkinson’s Disease Treatment Current Standard of Care CDNF Action: CDNF is a natural protein whose role is Despairing Illness 01 to protect neurons underserved for decades Parkinson’s Currently Treated With 01 Levodopa Since 1960’s Disease Modifying: Promotes recovery of

  3. Slide 3: Maintenance neuronal functionality and survival in long-lived organisms in challenging

    Maintenance neuronal functionality and survival in long-lived organisms in challenging • In humans, central neurons are generated during fetal development and early post-natal life, there is very limited capacity to generate of new neurons in adult brain • Neurons are highly polarized and have a hig

  4. Slide 4: In Parkinson's disease, several cellular mechanisms important for functionality and survival are impaired

    In Parkinson’s disease, several cellular mechanisms important for functionality and survival are impaired ENDOPLASMIC RETICULUM (ER) 4 www.herantis.com

  5. Slide 5: Maintenance of proteostasis

    Maintenance of proteostasis Proteins are the building blocks of everything in the body. Functionality of all cells (particularly neurons) depends on the balance of the three cornerstones of proteome regulation: synthesis, folding and degradation. If any of these becomes dysfunctional, problems will

  6. Slide 6: Lewy body pathology: accumulation of aggregated alpha-synuclein protein is characteristic for Parkinson's

    Lewy body pathology: accumulation of aggregated alpha- synuclein protein is characteristic for Parkinson’s 6 www.herantis.com

  7. Slide 7: The discovery of CDNF

    The discovery of CDNF Nature 5 July 2007 Vol. 448, pp. 73-77 Letter Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo Päivi Lindholm1, Merja H. Voutilainen2, Juha Laurén1,4, Johan Peränen1, Veli-Matti Leppänen1, Jaan-Olle Andressoo1, Maria Lindahl1, Sanna Janhunen

  8. Slide 8: Structure of human CDNF protein

    Structure of human CDNF protein 8 8 www.herantis.com

  9. Slide 9: CDNF is not another GDNF! Many important differences…

    CDNF is not another GDNF! Many important differences… • Structure GDNF ○ In biology, structure dictates function ○ The structure of CDNF differs from all known growth factors or neurotrophic factors ○ Structure also is relevant for pharmaceutical Neurturin manufacturing and stability • Target pathwa

  10. Slide 10: CDNF promotes neuronal survival and recovery through multiple disease-relevant mechanisms

    CDNF promotes neuronal survival and recovery through multiple disease-relevant mechanisms • CDNF helps stressed or injured neurons survive and recover • Mechanisms relevant to PD • Promising data in several neurological diseases 10 10 www.herantis.com

  11. Slide 11: Intraputamenal CDNF infusions in Parkinson's

    Intraputamenal CDNF infusions in Parkinson’s • Parkinson’s is caused by the degeneration and death of dopaminergic neurons of the nigrostriatal pathway ○ Reduced striatal dopamine levels ○ Motor symptoms • Based on preclinical data: Putamen ○ CDNF promotes functional recovery of dopaminergic termina

  12. Slide 12: CDNF protects and recovers dopaminergic neurons in a rhesus monkey PD model

    CDNF protects and recovers dopaminergic neurons in a rhesus monkey PD model Vehicle control 150 µg CDNF 80% loss of dopaminergic neurons Doubled the number of dopaminergic neurons and fibers • Model: Established MPTP lesion in aged Rhesus monkey → True neurorestoration study with 80% loss of DA neur

  13. Slide 13: CDNF improves gross and fine motor symptoms in a rhesus monkey PD model

    CDNF improves gross and fine motor symptoms in a rhesus monkey PD model CDNF significantly improves motor symptoms by 53% in a MPTP rhesus model of PD at 3 months Improvement in Motor Symptoms • Gross motor functions measured with monkey Parkinsonian disability rating scale (MPRS) • Fine motor funct

  14. Slide 14: Summary

    Summary • In Parkinson’s, dopamine neurons die slowly and treatments like CDNF have in preclinical studies shown significant therapeutic potential in functional recovery of the degenerating neurons and neuronal functions • Optimally, a neurorestorative treatment like CDNF would be started soon after

Herantis Pharma — TreatER webinar 2020 on 6ix